



Unifying the care experience.

Appendix 4C



ASX Release

Appendix 4C – Q1 2021 Quarterly Cash Flow Report

23 April 2021 – Sydney, Australia – Oneview Healthcare PLC (ASX:ONE) a global healthcare technology company today released its Appendix 4C – Quarterly Cashflow report for the quarter ending 31 March 2021 (Q1 FY21).

Operational Highlights

- Oneview announced the launch of CXP Cloud Enterprise, the world's first and only cloud-based inpatient care experience platform, which is a key pillar of the Company's growth strategy.
- A partnership agreement was signed with Samsung SDS America, Inc. to offer a bundled solution for bedside digital services for hospitals in the United States. This program is formally launching in April 2021.
- Oneview was awarded ISO 27001 certification on 24 March 2021.
- An expansion contract for 75 devices was signed with an existing customer, Children's Hospital & Medical Center in Omaha, NA.
- Smaller expansion orders with other existing customers were signed in the quarter for a total of 107 devices.
- A tablet refresh was completed in UCSF in the quarter. The next phase of the project also commenced in Q1 2021, which will see the installation of 500 new WeTek Set Top Boxes, scheduled to be completed by Q3 2021.
- A hearing in the Supreme Court of Victoria, Commercial Court on 25 March in the case between Oneview Healthcare Pty. Ltd and Regis Aged Care Pty. Ltd. ordered the parties to provide discovery by 14 May 2021.

Directors M Kaminski (Chairman) | L Berkowitz | J Fitter | J Rooney

Oneview Healthcare plc

Block 2, Blackrock Business Park, Blackrock Co. Dublin, A94 H2X4 Ireland

P +353 1 524 1677 E info@oneviewhealthcare.com oneviewhealthcare.com

Irish Company Reg: 513842


ARBN 610 611 768

VAT Number 9853271T

Financial Highlights

Oneview financial management over the quarter saw net operating cash outflows reach a record low of €0.55 million, an improvement of 82% vs pcp.

The Company's cash balances as at 31 March 2021 totalled €5.8 million.



This improved position can be attributed to the following:

- Receipts from customers of €2.82 million, up 64% vs pcp.
- Payments for staff costs in the quarter were €2.12 million, down 27% vs pcp. Costs were slightly higher than the prior quarter due to engineering contractors utilised for the Cloud project and included non-recurring costs of €0.18 million.
- Administration and corporate costs of €0.76 million were slightly higher than the previous quarter, reflecting external consulting costs associated with achieving ISO 27001 certification.
- Marketing costs were higher than the previous quarter due to initiatives relating to the launch of the new CXP Cloud Enterprise product offering, including the launch of a new website.
- Transaction costs of €0.3 million in respect of the Q4 2020 equity raising were paid in Q1 2021.
- A PPP loan of US\$434,741 received in 2020 was forgiven in full and is included in grants received this quarter. A further PPP Round 2 forgivable loan of US\$312,500 was also received this quarter and is also included in grants received, as it will qualify in full for forgiveness.

Directors M Kaminski (Chairman) | L Berkowitz | J Fitter | J Rooney

Oneview Healthcare plc

Block 2, Blackrock Business Park, Blackrock Co. Dublin, A94 H2X4 Ireland

P +353 1 524 1677 E info@oneviewhealthcare.com oneviewhealthcare.com

Irish Company Reg: 513842

ARBN 610 611 768

VAT Number 9853271T



Unifying the care experience.

The Company also agreed to a A\$1 million strategic investment from StocksDigital and other investors in StocksDigital's extended network. Due to the nature of this investment, shareholder approval was sought at an EGM on April 15, and we were pleased that over 99% of shareholders voted in favour of each of the three resolutions tabled. The company received this fresh A\$1m investment from the relevant parties on 19 April 2021.

Payments to related parties of the entity and their associates in the quarter were comprised of directors' fees totalling €261,000, which included payments of €177,000 in respect of the final balance of retirement payments due to a retiring director.

Outlook

The Company has enjoyed a positive response to the launch of Cloud Enterprise from existing and prospective customers, with the response supporting a robust sales pipeline of new opportunities in both of its key markets. The Company has added two additional SaaS salespeople in the US this month to further capitalise on the first-mover advantage of this product.

NYU Langone this month placed expansion orders for 235 extra devices to be deployed in 3 new sites within their network. NYU Langone has also agreed to host a webinar for hospital leaders in the United States on 6 May 2021 entitled "How a Digital Patient Experience Platform Improved Our Patient, Family and Clinician Experience".

Oneview believes this advocacy and customer testimony will further support sales and expansion initiatives throughout the US. As this webinar is not open to investors, a recording will be shared on the company's website.

In discussing the quarter and the Company's future outlook, Oneview's CEO James Fitter said "This has been a transformational quarter for Oneview in many ways. The Company is proud to continue to not only improve its services offering for clients but continue its commitment to innovation.

I'd like to thank investors for their continued support, and also the staff at Oneview for the success the Company has experienced in achieving key engineering milestones. We look forward to updating the market on further developments as we continue to improve experience, optimize patient flow and deliver virtual care solutions for our customers around the world."

This announcement has been approved for release by the board of Oneview Healthcare plc.

Directors M Kaminski (Chairman) | L Berkowitz | J Fitter | J Rooney

Oneview Healthcare plc

Block 2, Blackrock Business Park, Blackrock Co. Dublin, A94 H2X4 Ireland

P +353 1 524 1677 E info@oneviewhealthcare.com oneviewhealthcare.com

Irish Company Reg: 513842

ARBN 610 611 768

VAT Number 9853271T



Unifying the care experience.

About Oneview Healthcare plc

For healthcare systems who lead on exemplary care, Oneview Healthcare plc provides digital tools for patients, families and caregivers to improve the care experience. Unifying a facility's systems, content and services into one digital Care Experience Platform at the point of care, Oneview helps providers to measure and improve experience, optimize patient flow, deliver virtual care and enable patients and families with dedicated touch and TV devices. Oneview has partnered with leading healthcare systems in the US, Australia, the Middle East and Asia to unify the care experience, in 55 hospitals.

Enquiries:

James Fitter, CEO

Helena D'Arcy, Interim CFO

Website : www.oneviewhealthcare.com

Directors M Kaminski (Chairman) | L Berkowitz | J Fitter | J Rooney

Oneview Healthcare plc

Block 2, Blackrock Business Park, Blackrock Co. Dublin, A94 H2X4 Ireland

P +353 1 524 1677 **E** info@oneviewhealthcare.com oneviewhealthcare.com

Irish Company Reg: 513842

ARBN 610 611 768

VAT Number 9853271T

Appendix 4C

Quarterly cashflow report for entities subject to Listing Rule 4.7B

Name of entity

Oneview Healthcare PLC

ABN

610 611 768

Quarter ended ("current quarter")

31 March 2021

Consolidated statement of cash flows	Current quarter €'000	Year to date (3 months) €'000
1. Cash flows from operating activities		
1.1 Receipts from customers	2,817	2,817
1.2 Payments for		
(a) research and development	-	-
(b) product manufacturing and operating costs	(497)	(497)
(c) advertising and marketing	(50)	(50)
(d) leased assets	-	-
(e) staff costs	(2,115)	(2,115)
(f) administration and corporate costs	(763)	(763)
1.3 Dividends received (see note 3)	-	-
1.4 Interest received	-	-
1.5 Interest and other costs of finance paid	-	-
1.6 Income taxes paid	(2)	(2)
1.7 Government grants and tax incentives	613	613
1.8 Other – director's retirement payments	(177)	(177)
Other – working capital movements	(374)	(374)
1.9 Net cash from / (used in) operating activities	(548)	(548)

2.	Cash flows from investing activities		
2.1	Payments to acquire:		
	(a) entities	-	-
	(b) businesses	-	-
	(c) property, plant and equipment	(15)	(15)
	(d) investments	-	-
	(e) intellectual property	-	-
	(f) other non-current assets	-	-
2.2	Proceeds from disposal of:		
	(a) entities	-	-
	(b) businesses	-	-
	(c) property, plant and equipment	-	-
	(d) investments	-	-
	(e) intellectual property	-	-
	(f) other non-current assets	-	-
2.3	Cash flows from loans to other entities	-	-
2.4	Dividends received (see note 3)	-	-
2.5	Other (provide details if material)	-	-
2.6	Net cash from / (used in) investing activities	(15)	(15)

3.	Cash flows from financing activities		
3.1	Proceeds from issues of equity securities (excluding convertible debt securities)	-	-
3.2	Proceeds from issue of convertible debt securities	-	-
3.3	Proceeds from exercise of options	-	-
3.4	Transaction costs related to issues of equity securities or convertible debt securities	(318)	(318)
3.5	Proceeds from borrowings	-	-
3.6	Repayment of borrowings	(354)	(354)
3.7	Transaction costs related to loans and borrowings	-	-
3.8	Dividends paid	-	-
3.9	Other (provide details if material)	-	-
3.10	Net cash from / (used in) financing activities	(672)	(672)

4.	Net increase / (decrease) in cash and cash equivalents for the period		
4.1	Cash and cash equivalents at beginning of period	6,804	6,804
4.2	Net cash from / (used in) operating activities (item 1.9 above)	(548)	(548)
4.3	Net cash from / (used in) investing activities (item 2.6 above)	(15)	(15)
4.4	Net cash from / (used in) financing activities (item 3.10 above)	(672)	(672)
4.5	Effect of movement in exchange rates on cash held	184	184
4.6	Cash and cash equivalents at end of period	5,753	5,753

5.	Reconciliation of cash and cash equivalents at the end of the quarter (as shown in the consolidated statement of cash flows) to the related items in the accounts	Current quarter €'000	Previous quarter €'000
5.1	Bank balances	5,753	6,804
5.2	Call deposits		
5.3	Bank overdrafts		
5.4	Other (provide details)		
5.5	Cash and cash equivalents at end of quarter (should equal item 4.6 above)	5,753	6,804

6.	Payments to related parties of the entity and their associates (directors)	Current quarter €'000
6.1	Aggregate amount of payments to related parties and their associates included in item 1 (payments to directors)	261
6.2	Aggregate amount of payments to related parties and their associates included in item 2	-

Note: if any amounts are shown in items 6.1 or 6.2, your quarterly activity report must include a description of, and an explanation for, such payments

7. Financing facilities

Note: the term "facility" includes all forms of financing arrangements available to the entity. Add notes as necessary for an understanding of the sources of finance available to the entity.

- 7.1 Loan facilities
- 7.2 Credit standby arrangements
- 7.3 Other (please specify)
- 7.4 **Total financing facilities**

	Total facility amount at quarter end €'000	Amount drawn at quarter end €'000
7.1	-	-
7.2	-	-
7.3	-	-
7.4	-	-

7.5 **Unused financing facilities available at quarter end**

-

- 7.6 Include in the box below a description of each facility above, including the lender, interest rate, maturity date and whether it is secured or unsecured. If any additional financing facilities have been entered into or are proposed to be entered into after quarter end, include a note providing details of those facilities as well.

8. Estimated cash available for future operating activities	€'000
8.1 Net cash from / (used in) operating activities (Item 1.9)	(548)
8.2 Cash and cash equivalents at quarter end (Item 4.6)	5,753
8.3 Unused finance facilities available at quarter end (Item 7.5)	-
8.4 Total available funding (Item 8.2 + Item 8.3)	5,753
8.5 Estimated quarters of funding available (Item 8.4 divided by Item 8.1)	10.5

- 8.6 If Item 8.5 is less than 2 quarters, please provide answers to the following questions:

1. Does the entity expect that it will continue to have the current level of net operating cash flows for the time being and, if not, why not?

Answer:
N/A

2. Has the entity taken any steps, or does it propose to take any steps, to raise further cash to fund its operations and, if so, what are those steps and how likely does it believe that they will be successful?

Answer:

N/A

3. Does the entity expect to be able to continue its operations and to meet its business objectives and, if so, on what basis?

Answer:

N/A

Compliance statement

- 1 This statement has been prepared in accordance with accounting standards and policies which comply with Listing Rule 19.11A.
- 2 This statement gives a true and fair view of the matters disclosed.

Date: 23 April 2021

Authorised by: **BY THE BOARD**
(Name of body or officer authorising release – see note 4)

Notes

1. This quarterly cash flow report and the accompanying activity report provide a basis for informing the market about the entity's activities for the past quarter, how they have been financed and the effect this has had on its cash position. An entity that wishes to disclose additional information over and above the minimum required under the Listing Rules is encouraged to do so.
2. If this quarterly cash flow report has been prepared in accordance with Australian Accounting Standards, the definitions in, and provisions of, *AASB 107: Statement of Cash Flows* apply to this report. If this quarterly cash flow report has been prepared in accordance with other accounting standards agreed by ASX pursuant to Listing Rule 19.11A, the corresponding equivalent standard applies to this report.
3. Dividends received may be classified either as cash flows from operating activities or cash flows from investing activities, depending on the accounting policy of the entity.
4. If this report has been authorised for release to the market by your board of directors, you can insert here: "By the board". If it has been authorised for release to the market by a committee of your board of directors, you can insert here: "By the [name of board committee – eg Audit and Risk Committee]". If it has been authorised for release to the market by a disclosure committee, you can insert here: "By the Disclosure Committee".
5. If this report has been authorised for release to the market by your board of directors and you wish to hold yourself out as complying with recommendation 4.2 of the ASX Corporate Governance Council's *Corporate Governance Principles and Recommendations*, the board should have received a declaration from its CEO and CFO that, in their opinion, the financial records of the entity have been properly maintained, that this report complies with the appropriate accounting standards and gives a true and fair view of the cash flows of the entity, and that their opinion has been formed on the basis of a sound system of risk management and internal control which is operating effectively.